Protalix BioTherapeutics, Inc. (PLX) financial statements and ratios from SEC XBRL: revenue $52.74M (TTM), net margin -12.5%, revenue growth 27.1% YoY, P/E 10.1. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $52.74M |
| Net Margin | -12.5% |
| Revenue Growth (YoY) | 27.1% |
| FCF Growth (YoY) | 94.1% |
| P/E Ratio | 10.1 |
| EV / EBITDA | 6.6 |
| Price / Book | 2.67 |
| Price / Sales | 2.36 |
| FCF Yield | 0.2% |
| Altman Z-Score | -2.19 (distress) |
| Sector P/E (Healthcare) | 21.7 |
PLX overview · PLX earnings · PLX KPIs · PLX investor relations · PLX ownership · PLX peers · PLX filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.